Hepatocyte Death: A Clear and Present Danger

HARMEET MALHI, MARIA EUGENIA GUICCIARDI, AND GREGORY J. GORES

Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota

I. Introduction 1165
II. Modes of Cell Death 1166
   A. Apoptosis 1166
   B. Onotic necrosis 1169
   C. Necroptosis 1170
   D. Autophagy 1170
III. Basic Concepts of Hepatocyte Injury 1171
   A. The hepatocyte and its hostile environment 1171
   B. The liver as a component of the innate immune system 1175
IV. Pathobiology of Hepatic Apoptosis and Disease Relevance 1175
   A. Death ligands and receptors 1175
   B. Toll-like receptors 1181
   C. Lysosomal pathway 1182
   D. Endoplasmic reticulum stress 1183
V. Therapeutic Strategies for Liver Injury 1184
   A. Protease inhibitors 1185
   B. Kinase inhibitors 1186
VI. Conclusions 1186

Malhi H, Guicciardi ME, Gores GJ. Hepatocyte Death: A Clear and Present Danger. Physiol Rev 90: 1165–1194, 2010; doi:10.1152/physrev.00061.2009.—The hepatocyte is especially vulnerable to injury due to its central role in xenobiotic metabolism including drugs and alcohol, participation in lipid and fatty acid metabolism, its unique role in the enterohepatic circulation of bile acids, the widespread prevalence of hepatotropic viruses, and its existence within a milieu of innate immune responding cells. Apoptosis and necrosis are the most widely recognized forms of hepatocyte cell death. The hepatocyte displays many unique features regarding cell death by apoptosis. It is quite susceptible to death receptor-mediated injury, and its death receptor signaling pathways involve the mitochondrial pathway for efficient cell killing. Also, death receptors can trigger lysosomal disruption in hepatocytes which further promote cell and tissue injury. Interestingly, hepatocytes are protected from cell death by only two anti-apoptotic proteins, Bcl-xL and Mcl-1, which have nonredundant functions. Endoplasmic reticulum stress or the unfolded protein response contributes to hepatocyte cell death during alterations of lipid and fatty acid metabolism. Finally, the current information implicating RIP kinases in necrosis provides an approach to more fully address this mode of cell death in hepatocyte injury. All of these processes contributing to hepatocyte injury are discussed in the context of potential therapeutic strategies.

I. INTRODUCTION

The liver is an organ of immense complexity that has fascinated mankind since antiquity. The liver is essential for survival as no other organ can compensate for its multiplicity of functions. Multiple phenotypically distinct cell types comprise the liver. The predominant liver cell is the hepatocyte, a polarized epithelial cell. Hepatocytes regulate intermediary metabolism, detoxify endo- and xenobiotics, manufacture critical circulating proteins, and generate bile acid-dependent bile flow. The other polarized epithelial cell type in the liver is the cholangio
cyte, which lines the bile ducts and modulates bile flow (242). The vascular structures in the liver are the sinu-
soids, which are lined by a fenestrated endothelial cell type (62). The sinusoidal pericyte is also termed the hepatic stellate cell and in addition to its pericyte func-
tions can be transformed into a myofibroblast pheno-
type (79); activated myofibroblasts contribute to the exuberant wound healing response of the liver during chronic disease states. The liver is also enriched in resident tissue macrophages termed Kupffer cells, natural killer (NK), and natural killer-T (NKT) cells, making it a key organ of the innate immune system (83). These cells of the innate immune system often contribu-
te to and amplify liver injury.
Sinusoidal endothelial cells, cholangiocytes, and hepatocytes are each uniquely susceptible to various types of injury and play a role in distinct clinically recognized syndromes of liver injury. For example, cholangiocyte damage results in impairment of bile flow or cholestasis (242), sinusoidal endothelial cell injury is manifest as the sinusoidal obstruction syndrome (62), while hepatocyte injury results in liver dysfunction. Any chronic form of liver damage can result in myofibroblast activation, dysregulated hepatic fibrosis, and cirrhosis (79). Indeed, cirrhosis is the most nefarious consequence of continuous liver injury, as it results in portal hypertension, liver failure, and death. Continuous cell turnover and hepatic fibrosis are also permissive for the development of hepatocellular carcinoma, a frequent complication of chronic liver diseases (Figs. 1 and 2). Because most forms of liver injury involve hepatocytes as either a primary or secondary target, we focus this review on hepatocyte injury. Also, prior articles in Physiological Reviews have focused on cholestasis that involves cholangiocytes and also on stellate cell biology (79, 257). However, where these overlap, we will also discuss mechanisms of injury to the other cell types.

II. MODES OF CELL DEATH

Several modes of cell death have been classified by consensus agreement including apoptosis, necrosis, necroptosis, autophagy, and cornification (Table 1) (144). This classification of cell death is based primarily on morphological criteria, and each form of cell death is described in detail below, except cornification which is limited to skin tissue. Although the term programmed cell death is often used in the literature, this simply refers to a genetically controlled process. However, as genes modulate cell susceptibility to multiple processes including accidental cell death (115), the term lacks specificity and will not be used in this review.

A. Apoptosis

1. Definition and hepatic consequences of apoptosis

Apoptosis is derived from a Greek word that describes “leaves falling from a tree” and was first used by Kerr et al. (134) to define a specific morphological aspect of cell death characterized by membrane blebbing, shrinkage of the cell, chromatin condensation (pyknosis), and nuclear fragmentation (karyorrhexis). Scission of the cell into membrane defined bodies termed apoptotic bodies that often contain micronuclei (nuclear fragments) is a hallmark of apoptosis. These apoptotic bodies express “eat me” signals on the external cell membrane, such as phosphatidylserine, resulting in their engulfment by phagocytic cells (256). In the liver, both stellate cells and Kupffer cells, the resident macrophages of the liver, can phagocytose apoptotic bodies (31, 33, 124).

Hepatocyte apoptosis can be considered to be a pivotal step in most forms of liver injury (Fig. 1). Enhanced hepatocyte apoptosis is tightly coupled with inflammation and fibrosis (110, 252, 269). Hepatocyte injury and turnover are also essential for liver cell cancer, and cell deletion by apoptosis stimulates hepatocyte mitogenesis. For example, conditional deletion of a key anti-apoptotic protein in the hepatocyte, Mcl-1, results not only in hepatocyte apoptosis, but in the pressure for constant cell turnover which also promotes hepatocellular carcinogenesis. Apparently, the cell turnover due to apoptosis, the fibrotic extracellular matrix, and constant pro-apoptotic stimulus, are permissive for the development of liver cancer.

The mechanisms by which apoptosis promotes inflammation relate to the activation of the resident macrophages in the liver, the Kupffer cells (Fig. 2). Following engulfment of apoptotic bodies, Kupffer cells express the death ligands tumor necrosis factor (TNF)-α, TNF-related apoptosis-inducing ligand (TRAIL), and Fas ligand (FasL) (31), capable of inducing death receptor-mediated apoptosis in hepatocytes, which may further aggravate liver inflammation and fibrosis. Engulfment of apoptotic bodies by macrophages also induces FasL expression (135), which exerts a proinflammatory activity (41). As a consequence of chronic liver injury, hepatic stellate cells (HSC) undergo a process of activation (Fig. 2). When activated...
HSC engulf the apoptotic bodies resulting from hepatocyte apoptosis, they produce profibrogenic cytokines (such as transforming growth factor-$\beta_1$) and type I collagen (33). Recent information suggests that apoptotic cells also release the nucleotides ATP and UTP, which can bind to purinergic receptors on macrophages and HSC, especially the P2Y$_2$ receptor (67). As P2Y$_2$ receptors are present on HSC (64), release of nucleotides by apoptotic hepatocytes is likely an additional mechanism by which apoptosis promotes hepatic fibrosis. Therefore, emerging concepts implicate excessive apoptosis as a keystone in hepatic inflammation and fibrogenesis.

### TABLE 1. Modes of cell death

<table>
<thead>
<tr>
<th>Cell Death Mode</th>
<th>Morphology</th>
<th>Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apoptosis</td>
<td>Cell shrinkage, Blocks within organelles, Nucleus fragmentation, Cell fragmentation</td>
<td>Caspase inhibitor</td>
</tr>
<tr>
<td>Necrosis</td>
<td>Cellular swelling, Blebs devoid of organelles, Moderate chromatin condensation, Rupture of plasma membrane</td>
<td>Necrostatin-1</td>
</tr>
<tr>
<td>Autophagy</td>
<td>Cytoplasmic vacuolization, Double membrane vacuoles, No chromatin condensation</td>
<td>3-Methyladenine</td>
</tr>
</tbody>
</table>

**FIG. 2.** Cellular mechanisms of hepatic injury and fibrosis due to hepatocyte apoptosis. Hepatocyte apoptosis results in the formation of apoptotic bodies. Engulfment of apoptotic bodies by liver resident macrophages or Kupffer cells enhances their expression of death ligands such as TRAIL, Fas, and tumor necrosis factor (TNF)-$\alpha$. These death ligands in a feed-forward loop further promote hepatocyte apoptosis and generation of apoptotic bodies. Engulfment of apoptotic bodies by stellate cells promotes their activation and enhances their development into myofibroblasts, which secrete collagen type I and transforming growth factor (TGF)-$\beta_1$, promoting development of fibrosis and cirrhosis. Recently, apoptotic cells were shown to release the nucleotides UTP and ATP, which bind P2Y$_2$ purinergic receptors on myofibroblasts enhancing their secretion of collagen. The constant cell turnover and proapoptotic pressure are also permissive for the development of hepatocellular carcinoma.

2. Caspases

Biochemically, apoptosis is commonly initiated and executed by activation of intracellular enzymes termed caspases as a contraction for cysteine-dependent aspartate specific protease (Fig. 3) (213). Like other intracellular proteases, caspases are synthesized as zymogens that must undergo proteolytic cleavage to exert proteolytic activity. Caspases have a dominant specificity for protein substrates containing four- or five-amino acid sequences containing an aspartate residue in the P1 position (the amino acid on the NH$_2$-terminal side of the scissile bond), a unique feature of this class of proteases. Caspases themselves must be cleaved at aspartate residues for activa-
The conserved pentapeptide QACXG motif within the large subunit. Rameric active form of protease. The catalytic cysteine is embedded in the 20- and 10-kDa polypeptides that oligomerize to form the heterotetramer active form of protease. The catalytic cysteine is embedded in the conserved pentapeptide QACXG motif within the large subunit.

Mitochondrial outer membrane permeabilization

Mitochondrial outer membrane permeabilization (MOMP) releasing several activators of apoptosis into the cytosol including cytochrome c, second activator of mitochondrial apoptosis (SMAC), endonuclease G, high temperature requirement A2 (HtrA2), and apoptosis-inducing factor (AIF) (217). Egress of cytochrome c from the mitochondrial intramembrane space into the cytosol promotes formation of a protein complex comprising caspase 9 and apoptosis activating factor-1 (APAF-1) (52, 91). This complex termed the apoptosome results in caspase 9 activation leading to effector caspases 3, 7, and 6 activation and hepatocyte apoptosis.

The Bcl-2 (B-cell lymphoma-2) family is a group of proteins that regulate mitochondrial dysfunction during apoptosis. The family comprises both pro- and anti-apoptotic members interacting with each other and/or with the mitochondria to control the integrity of the outer mitochondrial membrane (OMM) (296). Bcl-2 proteins are divided into three subsets, based on number of Bcl-2 homology domains (BH1–4 domains) comprising the protein: 1) the anti-apoptotic members Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and A1, containing BH domains 1–4; 2) the pro-apoptotic multidomain effector proteins Bax, Bak, and Bok containing BH domains 1–3; and 3) the BH3-only pro-apoptotic members Bid, Bim, Bad, Bik, Bmf, Hrk, Noxa, and Puma, which function as initial sensors of different apoptotic signals. Despite this accepted classification based on their structure and function, the specific protein-protein interactions between members of the Bcl-2 family are still highly controversial. The pro-apoptotic proteins Bak, which normally resides in the OMM, and Bax, which translocates from the cytosol to the OMM after an apoptotic stimulus, are directly responsible for causing MOMP by inserting in the membrane after a conformational change and forming proteolipid pores (155). These proteins are essential for MOMP, as cells simultaneously lacking Bax and Bak are resistant to multiple pro-apoptotic stimuli (166, 279). However, the mechanism by which Bax and Bax are activated has not been completely clarified. In a model referred to as the “direct activation model,” a subset of BH3-only proteins termed “direct activators” (including Bid, Bim, and Puma) can either be sequestered by the pro-survival proteins, or bind directly to Bax and Bak, inducing their conformational changes and activation (136). All the other BH3-only proteins named “sensitzizers” or “deregressors” only bind to the pro-survival proteins, thus lowering the capacity of the pro-survival proteins to sequester the direct activators or dissociating the pro-survival proteins from binding to and preventing activation of Bax and/or Bak (42) (Fig. 4).

By whatever mechanism they function, the BH3-only proteins are key initiators of the mitochondrial cell death pathway.

Bcl-2, the founding member of the Bcl-2 family, is not expressed in hepatocytes (39, 149, 263), while mice genetically deficient for Bcl-w or Bfl-1/A1 have no specific liver phenotype under basal conditions (100, 214, 223). In contrast, mice in which either Bcl-xL or Mcl-1 has been conditionally deleted in hepatocytes have a pronounced and similar phenotype characterized by significant hepato-

![Caspase structure. Caspases consist of a catalytic domain organized in a large subunit (~20 kDa), a small subunit (~10 kDa), and a prodomain of variable length. Effector caspases exhibit a short prodomain, whereas initiator caspases have long prodomains that direct binding to protein complexes. Caspase-directed cleavages at aspartate residues in a linker region between the large and the small subunit and between the prodomain and the large subunit generate the formation of the 20- and 10-kDa polypeptides that oligomerize to form the heterotetrameric active form of protease. The catalytic cysteine is embedded in the conserved pentapeptide QACXG motif within the large subunit.](http://physrev.physiology.org)
tocyte apoptosis. Indeed, although Bcl-x L and Mcl-1 are both multidomain anti-apoptotic proteins, hepatocyte deficiency in either one of these anti-apoptotic proteins results in spontaneous caspase 3/7 activation, hepatocyte apoptosis, and elevated levels of serum aminotransferases (252, 269). These observations are consistent with nonredundant, cytoprotective functions for both proteins in the hepatocyte, or with predominant expression of either Bcl-xL or Mcl-1 in individual hepatocytes, an unlikely but testable hypothesis. Alternatively, either Bcl-x L or Mcl-1 is modified in the hepatocyte such that it is incapable of maximal cytoprotection. Evidence for this latter concept exists as Bcl-xL is predominantly deamidated in the hepatocyte, a posttranslational modification which impairs its function (251). Inhibitory posttranslational modifications of Mcl-1 are also likely prevalent in hepatocytes. Thus the liver is subject to basal apoptotic stress which requires Mcl-1 plus Bcl-xL for survival. Liver injury in viral hepatitis may also occur as a result of viral proteins targeting Mcl-1 and/or Bcl-xL; for example, the hepatitis viral core protein may contain a BH3-only like domain which binds and targets Mcl-1 disabling its cytoprotective functions (195).

B. Oncotic Necrosis

1. Definition and hepatic consequences of necrosis

Unlike apoptosis, which is mediated by well-defined pathways, necrosis is thought to represent in large part an alternate but non-apoptotic mode of cell death. However, the mechanisms that result in the death of hepatocytes in response to necrosis (e.g., viral hepatitis) are less well understood. The death receptors Fas, TNF receptor 1 (TNF-R1), and TRAIL receptor 1/2 (TRAIL-R1/2) are major mediators of the apoptotic pathway in the liver. Upon stimulation by their cognate ligands, FasL, TRAIL, and TNF-α, respectively, the death receptors oligomerize and recruit different adaptor proteins which activate the initiator caspase 8 and likely caspase 10. Active caspase 8 cleaves the BH3-only protein Bid generating truncated Bid (t-Bid), which, following N-myristoylation (298), translocates to mitochondria and, in concert with active Bax and Bak, permeabilizes the OMM (Fig. 5). Bid is essential for Fas-mediated apoptosis in hepatocytes (294) and also appears to mediate hepatocyte apoptosis in Mcl-1 knockout mice (110). Since death receptors are ubiquitously expressed in the liver, hepatocytes may be subject to death receptor-induced Bid cleavage with subsequent Bax/Bak activation and cell death. Adequate cellular levels of the anti-apoptotic proteins Mcl-1 and/or Bcl-xL are, therefore, necessary to counteract the deleterious consequences of constitutive Bid activation.

FIG. 4. Bcl-2 family proteins regulate the mitochondrial pathway of apoptosis. Mitochondrial dysfunction is induced by homodimerization of Bax or Bak within the outer mitochondrial membrane. The homodimerization of these proteins can be directly stimulated by the BH3-only proteins Bim or Bid, and perhaps PUMA; hence, these three proteins are referred to as direct activators. Bax and Bak homodimerization is also kept in check by pro-survival Bcl-2 proteins, which in the hepatocyte are Bcl-xL and Mcl-1. The pro-survival function of these proteins can be repressed by the sensitizing BH3-only proteins Bad, Hrk, Bmf, NOXA, Bik, and PUMA. BH3-only protein repression of Mcl-1 and Bcl-xL then allows activation of Bax and/or Bak by an as yet unclear mechanism.

FIG. 5. Death receptor signaling and its interdigitation with the mitochondrial pathway of apoptosis. Ligation of a death receptor by its ligand results in the recruitment of procaspases 8 and 10 to a receptor complex via homotypic interactions with FADD (or the other adaptor protein TRADD). Within this complex, caspases 8 and 10 undergo auto-activation. Active caspase 8/10 can directly activate caspase 3, an executioner caspase (type I cells), or cleave Bid, a BH3-only member of the Bcl-2 family, to generate truncated Bid (tBid) which in turn induces mitochondrial dysfunction (type II cells). X-linked inhibitor of apoptosis (XIAP) determines which pathway results in cell death. In hepatocytes, activation of the mitochondrial pathway is necessary to overcome resistance by XIAP.
accidental form of cell death with simultaneous disruption of multiple pathways (e.g., anoxic cell death). Necrosis is derived from the Greek "necros" for corpse (115) and is characterized by oncosis (Greek for swelling) and the formation of plasma membrane blebs, which in contrast to the blebs of apoptosis are devoid of organelles (89, 180). In addition to cell swelling, organelle swelling is also a morphological feature of oncotic necrosis. A cellular feature of necrosis is rupture of the plasma membrane which occurs during a "metastable state" resulting in bleb rupture (180). Thus necrosis is accompanied by complete release of cellular constituents into the extracellular environment, a pathological phenomenon that can elicit a significant inflammatory response. Classic examples of oncotic necrosis include the following: 1) ATP depletion such as occurs during ischemia or hypoxic cell injury; 2) excessive formation of reactive oxygen species as takes place during reperfusion of ischemic tissue; 3) toxins including acetaminophen and other xenobiotics; 4) overwhelming tissue injury as occurs in acute fulminant liver failure; and 5) sustained increases in intracellular calcium as defined in multiple experimental conditions (217). The mode of cell death by toxic stimuli is often concentration dependent, with low concentrations more likely to induce apoptosis and high concentrations necrosis. Thus many of the stimuli listed above may induce both modes of cell death dependent on the severity of the insult.

2. RIP kinases

The signaling cascades culminating in necrosis have been more difficult to elucidate compared with the ample information regarding these events in apoptosis. The BH3-only protein Bmf has been implicated in necrosis, suggesting that apoptosis and necrosis may share death mediators in their pathways (112). However, recent data suggest members of the receptor interacting protein (RIP) family contribute to necrosis (76). RIP1 and RIP2 interact with death receptors and caspases through shared death domains (DD) and caspase recruitment domains (CARD). RIP3 interacts with RIP1 via a RIP homotypic interaction motif (RHIM). Activation of RIP3 may be key in cell death by necrosis as this kinase is an energy metabolism regulator and its uncontrolled and sustained activation can deplete the cell of ATP (44, 299). Necrostatin-1 inhibits members of this family and reduces necrotic injury providing a new tool to help identify necrosis in pathophysiological models (60). How RIP3 may trigger the mitochondrial permeability transition remains unclear. No tissue-specific pathways regarding hepatocyte necrosis have been defined to date.

3. Mitochondrial permeability transition

Mitochondrial dysfunction is a cardinal feature of oncotic necrosis and is characterized by permeability of the outer plus the inner mitochondrial membranes (IMM) (180), a phenomenon termed the mitochondrial permeability transition (MPT) (16, 217). This is in contrast to apoptosis which is associated primarily with selective permeabilization only of the OMM (143). The loss of the IMM permeability barrier results in a collapse of ion gradients across the IMM driving the mitochondrial membrane potential to that of the cytosol (16). The loss of the mitochondrial membrane potential (Δψm; ~180 mV) and the pH gradient (alkaline to the cytosol) dissipates the proton-motive force preventing oxidative phosphorylation. In the absence of oxidative phosphorylation, cellular ATP levels fall precluding maintenance of ion pumps and other cellular processes, all culminating in cell blebbing and swelling. The molecular characterization of the permeability transition has remained elusive. Although the voltage-dependent ion channel (VDAC) and the adenine nucleotide transporter (ANT) have been implicated in the formation of a giant megachannel spanning both membranes, knockout of either gene does not preclude development of the MPT (217). In contrast, knockout of cyclophilin D does inhibit development of the MPT and more importantly attenuates ischemic tissue injury (217). Thus mitochondrial dysfunction is a crucial event in both apoptosis and necrosis, although the molecular mechanisms are quite dissimilar.

C. Necroptosis

1. Definition and hepatic consequences of necroptosis

Necroptosis is a form of death receptor-mediated cytotoxicity occurring in cells in which caspase 8 is deleted or inhibited (82). By morphology, necroptosis resembles oncotic necrosis, although it is initiated by a classic apoptotic cue. RIP kinases, which are recruited to death receptor complexes, initiate and help execute the necrotic phenotype (57). However, given that caspase 8-deficient mice are resistant to Fas- and TNF-α-mediated cell death (132), it is unlikely that hepatocytes intrinsically undergo necroptosis, although this mode of cell death may potentially occur in pathophysiological conditions.

D. Autophagy

1. Definition and hepatic consequences of autophagy

Autophagy (self-digestion) is a catabolic cellular process dependent on lysosomes for its execution (193). Catabolism within a cell is heterogeneous, and in this context, many different forms of autophagy have been defined. Microautophagy refers to invagination of the lysosomal membrane with engulfment of its cytosolic contents, followed by pinching off into the lysosome for
degradation. In contrast, macroautophagy involves formation of a double membrane-bound structure within the cytoplasm, which encloses cellular organelles or cytosol, thus forming the autophagosome. The autophagosome then fuses with the lysosome, its outer membrane becomes part of the lysosome, and the inner membrane-bound cargo is degraded within the lysosome. Chaperone-mediated autophagy involves direct transport of soluble proteins with the consensus pentapeptide sequence KFERQ via the chaperone heat shock cognate 70 (hsc70) to the lysosomal docking protein lysosome-associated membrane protein 2A (LAMP2A) followed by translocation into the lysosome for degradation. Much has been learned about autophagy in the preceding decade, primarily on a cellular level. Advances are being made in understanding its role at an organismal level.

Macroautophagy (referred to as autophagy hereafter) leads to degradation of obsolete organelles and cytosol, but it also occurs under conditions of nutrient deprivation. In a homeostatic sense, autophagy allows recycling of cellular constituents and, under conditions of starvation, promotes cellular survival by catabolism. Genetic screens in yeast have led to the identification of autophagy-related genes (Atg), starting with Atg1. Subsequently, mammalian autophagy genes have been identified as well. This has been followed by advances in understanding of the formation of autophagosomes within cells, regulation of autophagy, and its roles in pathophysiology. Autophagy has since then been linked to cell survival under nutrient deprivation and growth factor withdrawal (21, 172) and is under the inhibitory control of mTOR (mammalian target of rapamycin) (172). Autophagy has also been linked to cell death, innate immunity, adaptive immunity, and tumorigenesis. Morphologically, autophagic cell death is defined by the massive cytoplasmic accumulation of autophagosomes in dying cells without chromatin condensation, a hallmark of apoptosis (144). Although autophagosomes have been observed in many dying cells, this association does not imply that autophagy is mediating their cell death. Indeed, autophagy is protective in the setting of dying cells (28). In vivo, developmental cell death of the larval salivary gland of Drosophila occurs by autophagy (156). In the liver, autophagy is a prominent survival mechanism under nutrient deprivation (293). Aggregation-prone mutant α-antitrypsin is also cleared from the liver by autophagy (208). Mice deficient for Atg-7 in the liver demonstrate impaired adaptation to starvation, organelle turnover, accumulation of aggregated proteins and organelles, and hepatomegaly (140). Recent studies have demonstrated a role for autophagy in lipid metabolism and storage (240, 241); however, its role in fatty liver disease is unclear. Thus, overall, autophagy seems to be a pro-survival, protective pathway in the liver, and its role in liver injury, if any, remains to be elucidated.

III. BASIC CONCEPTS OF HEPATOCYTE INJURY

Disturbances of hepatic function and/or accentuated activation of the innate immune system cause liver stress, endangering hepatocyte survival. Indeed, biomarkers of hepatocyte injury such as serum aminotransferases are present in all humans. What constitutes an elevation of these biomarkers and, therefore, the cutoffs for a “healthy liver” are uncertain and a subject of clinical interest (137). However, the mere presence of aminotransferases in the circulation implies basal hepatocyte stress and turnover, and perhaps some level of hepatocyte injury is simply to be expected given the magnitude and variety of hepatocyte functions.

A. The Hepatocyte and Its Hostile Environment

Liver damage is common in medical practice given the worldwide use of alcohol, pharmacological use of drugs and medicinal use of unregulated compounds (e.g., herbal compounds, weight loss supplements, etc.), hepatotropic viruses, attack by free fatty acids in the metabolic syndrome, immune-mediated inflammatory processes afflicting the liver, genetic conditions, and other less common disease states. These pathobiological conditions and the unique features of the liver that render it susceptible to injury are summarized below.

1. Portal blood flow, xenobiotic biotransformation, and hepatotoxicity

Xenobiotics (chemical compounds, such as a drug or ethanol, that are foreign to the body of a living organism) are a common cause of liver injury. The susceptibility of the liver to xenobiotic-mediated injury is due to the unique vascular and metabolic features of the liver. Approximately 75% of hepatic blood flow comes directly from the gastrointestinal viscera and spleen via the portal vein; the other 25% of hepatic blood flow is derived from the hepatic artery. Portal blood is enriched in ingested xenobiotics absorbed by the gut which are delivered at high concentrations to the liver. The liver has evolved to defend the organism from the unintended xenobiotic exposure by developing a complex array of detoxifying enzymes including hydroxylation, oxidation, and conjugation reactions (131). Although this detoxification system renders many xenobiotics harmless and facilitates their elimination from the body, it also has the potential to convert chemical compounds into highly reactive intermediate compounds. These reactive molecules can be quite injurious to the liver. An example of liver injury by this mechanism is acetaminophen (121) (Fig. 6).

Acetaminophen, when ingested in amounts that overwhelm conjugation reactions, is converted in the hepato-
cyte to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which results in depletion of hepatocyte glutathione stores rendering the hepatocyte vulnerable to oxidative stress. NAPQI can also react with proteins in a process termed protein arylation. The resultant oxidative stress and protein dysfunction causes mitochondrial dysfunction and activation of other deleterious intracellular cascades culminating in loss of cell viability by both necrosis and apoptosis (141). Aiding the ability of the hepatocyte to generate glutathione by supplying exogenous N-acetylcysteine is a clinical strategy to ameliorate acute acetaminophen intoxication (243). What is most interesting is that the initial wave of hepatotoxicity by acetaminophen is likely not sufficient to cause fatal liver injury; rather, the secondary activation of the innate immune system is what most likely destroys the liver. Hepatocyte death by necrosis releases intracellular constituents such as DNA, uric acid, and nucleotides that are recognized by the innate immune system as danger-associated molecular pattern (DAMPs) signals (169) (Fig. 6). In particular, DAMPs result in activation of the inflammasome which consists of Nalp3 (NACHT, LRR, and pyrin domain-containing protein 3), ASC (apoptosis-associated speck-like protein containing CARD), and procaspase 1. Activation and autoproteolytic cleavage of procaspase 1 yields active caspase 1 in the inflammasome. Independent of the inflammasome, HMGB1-induced TLR9 activation results in enhanced expression of pro-interleukin (IL)-1β and pro-IL-18. Cleavage of pro-IL-1β and pro-IL-18 to active IL-1β and IL-18 is catalyzed by caspase 1. CD24 and Siglec-G are negative regulators of HMGB1-activated innate immune responses. HMGB-1 can bind LPS and enhance TLR4 activation, as well as activate TLR2; however, the contribution of these two pathways to AAP-induced liver injury has not yet been elucidated.
deficient for IL-1β are resistant to death from acute acetaminophen hepatoxicity (117). Acetaminophen toxicity is an example of the complex but deadly interactions between xenobiotic metabolism and the hepatic innate immune system.

Alcohol (ethanol; also a xenobiotic) consumption is common in many societies and can be associated with severe liver injury in a subset of heavy consumers. Alcohol induces expression of the detoxifying enzyme Cyp2E1 which generates reactive oxygen species as it metabolizes its substrates (171). Alcohol induction of Cyp2E1 can also predispose to xenobiotic associated liver injury; for example, chronic alcohol use sensitizes the liver to injury by acetaminophen by enhancing its biotransformation to toxic intermediary compounds (53). Alcohol also modulates the cytokine environment of the liver and evokes the expression of the inflammatory cytokines TNF-α, IL-1, and IL-6 (181). These cytokines are likely generated through Toll-like receptor 4 on Kupffer cells (181) (Fig. 7). Alcohol-associated liver injury also represents a complex, and at this time poorly understood, relationship between biotransformation and the innate immune system. Unfortunately, unlike other human inflammatory diseases, alcohol-induced acute liver injury is not improved by anti-TNF-α directed therapy (24), and thus, considerable more work is necessary to understand this disease process.

2. Free fatty acids as toxic endobiotics

Excessive serum concentrations of free fatty acids (FFA) may be classified as potentially toxic nutrients or toxic endobiotics (compounds endogenous to a living organism). The metabolic syndrome, characterized by obesity and insulin resistance, is common in western societies. This medical condition is associated with elevated levels of circulating FFA (150). The excess serum FFA in the context of insulin resistance saturates the transport and storage capacity of adipocytes leading to their uptake by ectopic sites, including the liver. The surfeit of FFA results in their participation in nonoxidative pathways with potential deleterious consequences for the hepatocyte resulting in nonalcoholic fatty liver disease (NAFLD) (179). Indeed, this is currently the most common form of liver injury in Western societies afflicted with a rising incidence of obesity.

A subset of NAFLD individuals develop severe hepatic lipotoxicity, a syndrome referred to as nonalcoholic steatohepatitis (NASH) (1), which can progress to cirrhosis and its chronic sequela (66, 218). Although the liver in this syndrome is characterized by steatosis, current concepts indicate that FFA, and not their esterified product (triglyceride), mediate hepatic lipotoxicity as inhibitors of triglyceride formation actually potentiate liver injury (167, 290). Elevated serum FFA levels also correlate with liver disease severity (5, 55, 200). In vitro studies suggest saturated FFA, such as palmitic acid or stearic acid, as opposed to unsaturated FFA, such as oleic acid, are more pro-apoptogenic (84, 276). Consistent with FFA-mediated...
hepatocyte apoptosis as a pathogenic mechanisms in NASH, human NASH is characterized by increased hepatocyte apoptosis (71), and serum biomarkers of apoptosis are useful for identifying NASH in humans (285). Thus NASH appears to be, in part, a disease process due to FFA-mediated hepatocyte apoptosis.

3. Bile acids as toxic endobiotics

Bile acids are amphipathic planar molecules synthesized from cholesterol within the hepatocytes. After their synthesis, these compounds are secreted into the bile and enter the proximal small intestinal lumen where they participate in digestion. Bile acids are reabsorbed in the terminal ileum and are efficiently transported from the portal vein back into the hepatocyte, a physiological process termed the enterohepatic circulation (257). In bile, their concentrations are in the millimolar range, a relatively toxic concentration for these bioactive molecules. Bile acid homeostasis is, therefore, tightly regulated in health, and their cellular and tissue concentrations are restricted. However, in cholestatic conditions, their secretion into bile is impaired, resulting in their hepatic retention and accumulation. In these cholestatic conditions, hepatocytes are exposed to toxic bile acid concentrations that trigger hepatocyte injury. Thus any cholestatic process, regardless of its etiopathogenesis, can be associated with a secondary injury related to bile acid toxicity (107).

Primary bile acids, those synthesized by the liver, include the trihydroxy bile acid cholate and the dihydroxy bile acid chenodeoxycholate. Either bile acid can be conjugated to glycine or taurine (113). Chenodeoxycholate is more toxic than cholate, and glycine conjugates are more toxic than taurine conjugates (95). The toxicity profile mirrors their hydrophobicity with glycine conjugates of dihydroxy bile acids being more hydrophobic than the taurine conjugates of trihydroxy bile acids. Bile acids induce cell toxicity by promoting death receptor-mediated apoptosis by enhancing their expression and trafficking to the plasma membrane (107, 108, 245) (Fig. 8). Ursodeoxycholate, a epimer of chenodeoxycholate, has hydrophilic properties and is able to ameliorate liver injury by toxic bile acids (4). Indeed, ursodeoxycholate is used clinically in the therapy of primary biliary cirrhosis and other cholestatic liver diseases (163).

4. Hepatotropic viruses

The liver is frequently afflicted by hepatotropic viruses. Acute liver injury can occur with infection due to hepatitis A virus, hepatitis E virus, cytomegalovirus, herpes simplex virus, and Epstein Barr virus. Chronic injury by hepatitis C virus (HCV) and hepatitis B virus (HBV) is even more common (68). HCV, an RNA virus, is usually acquired postnatally by parental exposure and results in chronic hepatitis in the majority of individuals. It frequently leads to liver cirrhosis, hepatic failure, and need for liver transplantation (29). HBV, a DNA virus, is commonly transmitted vertically at the time of birth in endemic areas of the world, but can also be transmitted parentally including sexual transmission (153). Like HCV, it also can chronically infect the host, eliciting chronic liver injury leading to cirrhosis and the sequelae of advanced liver disease. Hepatic injury by HCV and HBV is common worldwide. Liver injury in both HBV and HCV is thought to be mediated by adaptive and innate immune responses, as both immune responses can induce target cell apoptosis, a feature common in both viral liver diseases (25, 73).
B. The Liver as a Component of the In innate Immune System

The liver is the interface of the human biosphere where ingested nutrients and xenobiotics and gut-derived endobiotics borne by the portal vein encounter the internal milieu. Thus for the liver to possess innate immune functions seems teleologically sound. The microanatomy of the hepatic sinusoid is engineered to optimally present portal blood to hepatocytes and other cells of the innate immune system. Cell types that participate in innate immune responses in the liver include hepatocytes, cholangiocytes, HSC, liver sinusoidal endothelial cells (LSEC), dendritic cells, Kupffer cells, NK cells, and NKT cells. These cell types produce immunomodulatory cytokines, chemokines, acute phase proteins, complement, death ligands, and inflammatory mediators. Kupffer cells, HSC, LSEC, cholangiocytes, and dendritic cells can function as antigen presenting cells, and NK cells perform tumor and virus surveillance. Hepatocytes produce and secrete complement, acute phase proteins, and many cytokines including TNF-α and IL-6. LSEC function as efficient scavengers and tolerogenic antigen presenting cells (63, 271). Several subsets of dendritic cells exist in the liver, although in low numbers in normal liver (161). HSC also function as antigen presenting cells for stimulation of NKT cells as well as CD8+ and CD4+ T cells and participate in protective immunity against bacterial infections (287). Kupffer cells are the most numerous antigen-presenting cells in the liver; in addition, they participate in the clearance of apoptotic hepatocytes via phagocytosis, a process that promotes their activation and secretion of inflammatory cytokines (31).

The innate immune system in the liver displays several unique properties. It exhibits tolerance to a vast variety of stimuli, including lipopolysaccharide, while maintaining a rapid response to pathogens. In chronic viral infection, the innate immune system is undermined by viral factors, and after orthotopic liver transplantation, allograft tolerance can develop. Activation of the innate immune system is evident in acute and chronic liver diseases of varied etiology, in keeping with the defining features of innate immunity, i.e., nonspecificity, inborn and initial response. However, in the liver, even in chronic hepatitis, the ongoing activation of the innate immune system plays a key role in perpetuating inflammation. Utilizing dual models of acetaminophen-induced acute liver injury in mice, which results in predominantly necrotic cell death, as well as intraportal apoptotic hepatocyte DNA delivery, the role of toll-like receptor 9 (TLR9) in mediating liver inflammation, presumably via DAMPs released by dead cells, has been demonstrated (117). Furthermore, the release of DAMPs from damaged hepatocytes in acetaminophen-induced liver injury, and the activation of Kupffer cells by these signals has recently been demonstrated (184). The role of NK cells and NKT cells in secretion of interferon-γ (IFN-γ), neutrophil infiltration, chemokine secretion, and death ligand secretion has previously been demonstrated (168). Chronic inflammation is a hallmark of metabolic syndrome-associated nonalcoholic fatty liver disease (151, 159). Ethanol affects many components of the innate immune system, and chronic ethanol exposure promotes a proinflammatory milieu in the liver (152, 249). In chronic hepatitis C infection, NK cells promote inflammation and may facilitate persistence of infection (2). HBV can also activate the innate immune response in infected humans (77).

Recognition of immunogenic signals by the innate immune system is orchestrated via pathogen recognition receptors (PRR) that recognize a series of conserved microbial pathogen-associated molecular patterns (PAMPs). Similarly, damaged cells display DAMPs permitting their recognition by PRR. The PRR can be cytoplasmic or transmembrane. Cell membrane and cytoplasmic toll like receptors (TLRs), some members of the cytoplasmic nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), and cytoplasmic retinoic acid-inducible gene-1 (RIG-1)-like helicases (RLHs) recognize bacterial and viral products such as lipoproteins, peptidoglycans, double-stranded RNA (dsRNA), single-stranded RNA (ssRNA), short double-stranded RNA, and hypomethylated DNA (18, 118, 295). Interactions between these diverse pattern recognition receptors and their ligands can be promiscuous or specific, e.g., TLR4 is activated by the bacterial endotoxin lipopolysaccharide (LPS), and RIG-1 serves as a promiscuous sensor for intracellular dsRNA. DAMPs are intracellular molecules within intact cells, distinct from PAMPs, which have an immunomodulatory function. Several intracellular DAMPs, including uric acid, heat shock protein 70, high mobility group box (HMG)-1, and genomic double-stranded DNA, have been identified (142). DAMP-activated cell signals are distinct from PAMP-activated cell signals, as demonstrated in mice lacking CD-24 (40). These mice develop an exaggerated inflammatory response upon acetaminophen-induced liver injury, without exhibiting enhanced sensitivity to LPS. An integrated example of how these processes interdigitate to produce acetaminophen-related liver injury is depicted in Figure 6.

IV. PATHOBIOLOGY OF HEPATIC APOPTOSIS AND DISEASE RELEVANCE

A. Death Ligands and Receptors

1. Definition

Death receptors are a subgroup of the TNF/nerve growth factor (NGF) receptor superfamily (96). These cytokine receptors are type I transmembrane proteins...
(single membrane-spanning proteins with an extracellular \( \text{NH}_2 \)-terminus) with three distinct regions: an extracellular, \( \text{NH}_2 \)-terminal ligand-interacting domain characterized by serial cysteine-rich repeat domains, a membrane-spanning region, and an intracellular COOH-terminal domain characterized by a stretch of \( \sim 60-80 \) amino acids known as the “death domain” necessary for the initiation of cytotoxic signals when engaged by cognate ligands. Some death receptors, namely, Fas (CD95/APO1), TNF-R1 (p55/CD120a), TRAIL-R1 (death receptor 4-DR4), and TRAIL-R2 (death receptor 5-DR5/APO-2/KILLER), are ubiquitously expressed in the liver (69). These receptors bind to specific ligands, the majority of which are type II transmembrane proteins (single membrane-spanning proteins with an extracellular COOH terminus) belonging to the TNF family (96). Engagement of death receptors by their corresponding ligands (FasL, TNF-\( \alpha \), and TRAIL, respectively) triggers the so-called extrinsic pathways of apoptosis, a signaling cascade resulting in activation of effector caspases and cell death. In liver cells, the extrinsic pathway often partially overlaps with the intrinsic/mitochondrial pathway via cleavage and activation of Bid, which, in turn, results in MOMP and release of pro-apoptotic factors (Fig. 5). Because of its high exposure to toxic endobiotics, xenobiotics, and viruses, the liver has developed a sophisticated defense system to ensure the efficient removal of damaged or virus-infected cells in a tightly controlled manner, and the death receptors are a fundamental tool in this process. However, the high level of expression of death receptors can also work as a double-edged sword, as it renders the liver more susceptible to excessive apoptosis by this pathway. Indeed, every death receptor expressed in the liver has been implicated in liver injury in different pathological settings. The signaling pathways activated by these death receptors and their ligands, as well as their role in the pathophysiology of the liver, are discussed in greater detail below.

2. Fas signaling

Fas is constitutively expressed by every cell type in the liver (69). Its ligand, FasL, is mainly expressed as a transmembrane protein on the cell surface of activated cytotoxic T lymphocytes (CTL), which play a pivotal role in the removal of Fas-overexpressing, virus-infected, or mutated liver cells from healthy livers (15, 170). In certain pathological conditions, such as alcoholic hepatitis and Wilson’s disease, FasL can also be expressed by hepatocytes and induce fratricide cell death of Fas-expressing hepatocytes, amplifying the tissue damage (80). Kupffer cells also express FasL in response to engulfment of apoptotic bodies, a process that may, under pathological conditions, exacerbate hepatocyte apoptosis and liver injury and promote liver inflammation and fibrosis (31).

The trimeric FasL binds to preoligomerized Fas on the plasma membrane to initiate the signaling cascade (239). Ligand binding induces a conformational change in the receptor intracellular domain which results in recruitment of the adaptor protein FADD (Fas-associated protein with death domain) and pro-caspase 8 and/or 10, after relocalization of the receptor to lipid rafts (96). Multiple receptors are then recruited to the lipid rafts to form larger aggregates that are subsequently internalized via clathrin-mediated endocytosis and delivered to the early endosomal compartment, a step required for efficient complex formation and amplification of the death signal (157). This complex, comprising Fas, FasL, FADD, and caspase 8, is referred to as death-inducing signaling complex (DISC). The long and short splicing variants of cellular FLICE/caspase 8 inhibitory protein (c-FLIPL and c-FLIPS) can also be recruited to the Fas DISC (259); they generally exert an anti-apoptotic function by antagonizing caspase 8 activation, although c-FLIPL has also been shown to promote Fas-induced caspase 8 activation through the formation of caspase 8:cFLIPL\( _L \) heterodimers (36, 189). High local concentrations of caspase 8 led to its activation by self-processing, which, in turn, start a signaling cascade resulting in the activation of effector downstream caspases, such as caspases 3, 6, and 7 (227, 237). However, the pathway to activate effector caspases differs in distinct cell types (228) (Fig. 5). In the so-called type I cells, such as lymphocytes and thymocytes, active caspase 8 proceeds to directly cleave and activate downstream effector caspases; mitochondria are not required for caspase activation in these cells but are engaged later in an amplification loop to maximize the death signal. Indeed, these cells undergo apoptosis even when the anti-apoptotic proteins Bcl-2 and Bcl-xL are overexpressed (229). Conversely, type II cells, such as hepatocytes, depend on caspase 8 cleavage of Bid and consequent mitochondria dysfunction to activate the effector caspases; consistently, Bid knockout hepatocytes are resistant to Fas-mediated apoptosis whereas thymocytes are sensitive (294). As expected, Fas-mediated apoptosis can be blocked by overexpression of Bcl-2 or Bcl-xL in type II cells (229). This selective response to Fas stimulation was initially attributed to the levels of activated caspase 8 generated at the DISC, with large amounts of caspase 8 being able to bypass the mitochondria and directly activate the effector caspases, and small amounts being sufficient to cleave Bid and engage the mitochondria, but not to activate the effector caspases (228). However, recent studies suggest that XIAP (X-chromosome linked inhibitor of apoptosis protein) may be the critical discriminator between type I and type II apoptosis signaling (127) (Fig. 5). Indeed, XIAP is stabilized by association with active caspase 3 in wild-type mouse hepatocytes during Fas-mediated apoptosis, preventing further progression of the apoptotic cascade, and cell death can only
be achieved after mitochondrial dysfunction and release of the endogenous XIAP inhibitor SMAC/DIABLO (second mitochondria-derived activator of caspases/direct IAP-binding protein with low pl), which overcomes this blockage. However, when the mitochondrial pathway is inhibited, such as in Bid-deficient hepatocytes, Fas-mediated activation of effector caspases and apoptosis can be induced by depletion of XIAP, suggesting that effector caspases are indeed activated directly by caspase 8, but are inhibited by binding to XIAP. Loss of XIAP, therefore, turns hepatocytes into type I cells (127). Indeed, this pathway is so critical for hepatocyte apoptosis that mutants of cytochrome c (KA allele) which do not bind APAF-1 (resulting in failure to activate caspase 9) do not inhibit Fas-mediated liver injury (102). Finally, it should be noted that the dependence of hepatocytes on Bid for Fas-mediated cell death is a plastic phenomenon; in vitro cultured murine hepatocytes may resemble type I cells, and high concentrations of FasL may also result in type I signaling in vivo (232, 274).

3. Fas in liver pathobiology

Dysregulation of Fas apoptosis has been associated with several liver diseases (81). Toxic bile acids accumulating within the hepatocyte in cholestatic disease are known to induce hepatocyte apoptosis in a Fas-mediated, FasL-independent manner (70). Elevated intracellular concentrations of bile acids can induce Fas translocation from the cytosol and Golgi complex to the plasma membrane, where the increased surface density facilitates its oligomerization and initiation of the apoptotic signal (245) (Fig. 8). Consistently, Fas-deficient lpr mice are more resistant to liver injury after bile duct ligation (192).

Liver injury in viral hepatitis, both from HBV and HCV, is characterized by increased apoptosis; however, apoptosis is not caused by the virus, which by itself has a moderate cytopathic effect on the host cell, but rather by the host immune response to viral antigens. Although Fas-mediated apoptosis is not the only death pathway activated in viral hepatitis, it certainly plays a crucial role in the elimination of infected cells by CTL, as demonstrated by areas of FasL-positive infiltrating mononuclear cells in the liver of HBV- and HCV-infected patients (80, 111, 194). Consistently, Fas expression is increased in the liver of patients with chronic hepatitis B and C, although it is not clear whether this is regulated by viral proteins or by the inflammatory cytokines (80, 111, 174, 194). Fas-mediated apoptosis is also enhanced in the liver of patients with alcoholic hepatitis, where expression of both Fas and FasL is elevated compared with healthy livers, rendering the hepatocytes more sensitive to Fas-mediated apoptosis both by CTL and by autocrine and/or paracrine mechanisms (199). Finally, Fas expression and hepatocyte apoptosis are elevated in the liver of NASH patients, and sensitivity to Fas is increased in steatotic livers compared with normal livers, suggesting Fas-mediated cell death is an important feature of NASH (71, 72). Whereas increased Fas apoptosis is associated with liver diseases, the opposite is also true. Downregulation of Fas or inactivating mutations in the Fas death domain are, indeed, very frequent in human tumors, including hepatocellular carcinoma, and are associated with increased resistance to Fas-mediated apoptosis and poor prognosis (105, 120, 247, 291). Interestingly, although congenital or somatic mutations in the Fas death domain are fairly common, tumors very rarely display loss of heterozygosity, suggesting that maintaining one wild-type receptor may confer an oncogenic advantage (209). This advantage could be explained by the evidence that Fas-induced apoptosis requires two functional Fas alleles to ensure efficient DISC formation, whereas, in contrast, only one functional allele is sufficient to activate NF-kB and promote cell survival (158).

4. TRAIL signaling

DR4 (TRAIL-R1) and DR5 (TRAIL-R2) trigger apoptosis upon engagement by their natural ligand TRAIL (206, 207). Although both DR4 and DR5 are expressed in the liver at comparable levels (88), TRAIL binding affinity seems to be higher for DR5 at physiological temperatures (258), and, consistently, DR5 generally plays a more important role in TRAIL-mediated apoptosis (133). In addition, TRAIL also binds two “decoy receptors,” TRAIL-R3 (DcR1 or TRID or LIT) and TRAIL-R4 (DcR2/TRUND), so called because of their inability to induce cell death, due to either lack of the death domain (TRAIL-R3) or presence of a truncated, dysfunctional one (TRAIL-R4) (58, 59). Binding of TRAIL to these receptors can sometimes antagonize the apoptotic signal through DR4 and DR5. TRAIL is synthesized as a type II transmembrane protein and is expressed mainly by cells of the immune system, especially NK cells, NKT cells, and macrophages (88), and it is biologically active as a homotrimer (23). TRAIL-induced apoptosis is fundamental for maintaining T-cell homeostasis, as well as for the elimination of tumor and virally transformed cells (122, 244). Studies using TRAIL-deficient mice have, indeed, confirmed its function in antitumor immune surveillance (48). Despite the high expression of TRAIL and its receptors, normal hepatocytes are resistant to TRAIL-mediated cell death (90). On the other hand, liver cancer cells (as well as other tumors) often undergo apoptosis after TRAIL treatment, which prompted clinical trials for the use of TRAIL in cancer therapy (6). The reason for this different effect on transformed and nontransformed cells has not yet been completely clarified.

Binding of TRAIL to DR4 or DR5 is assumed to trigger similar signaling cascades, although some differ-
ences are likely to exist. Similar to Fas, the interaction between the ligand and its death receptors leads to the assembly of a multicomponent DISC at the cell membrane. The adaptor FADD is recruited to the receptor and functions as a docking protein to facilitate the recruitment of the initiator pro-caspase 8 and 10 to the receptor (145). The same distinction between type I and type II cells generally applies to TRAIL signaling as well (204), although it was originally referred to the Fas signaling pathway. Ligand-engaged DR4 and DR5 are rapidly endocytosed via both clathrin-dependent and clathrin-independent pathways in type I cells, but unlike Fas signaling, internalization of receptors is not required for transmission of its apoptotic signal (139). On the contrary, DR5 internalization is essential for TRAIL-induced apoptosis in hepatocytes and cholangiocytes (both examples of type II cells), suggesting that type I and type II cells have opposite requirements for receptor internalization during TRAIL-induced cell death (3). After TRAIL treatment of liver cells, DR5 is internalized and colocalizes with lysosomes, where it is believed to contribute to lysosomal membrane permeabilization (LMP) and lysosomal protease release into the cytosol. As hepatocytes and cholangiocytes heavily rely on LMP to mediate TRAIL killing, trafficking of receptor-bound DISC-containing vesicles to the lysosomes may explain the need for receptor internalization to initiate the apoptotic pathway in these cells. The release of lysosomal enzymes into the cytosol promotes mitochondrial dysfunction in liver cells, although the mechanisms involved are not fully understood (94). Prior studies, however, suggest that release of the lysosomal enzyme cathepsin B into the cytosol promotes activation of caspase 2 in hepatocytes, which, in turn, may facilitate efficient mitochondrial cytochrome c release and apoptosis (93). At the same time, mitochondrial dysfunction can also be induced by caspase 8-mediated cleavage of Bid and subsequent Bax/Bak activation, similarly to what was observed after Fas stimulation in type II cells.

5. TRAIL in liver pathobiology

TRAIL-mediated apoptosis is involved in the pathogenesis of viral hepatitis (196). Although hepatocytes are normally resistant to TRAIL-induced apoptosis, underlying pathological conditions, such as steatosis and viral infection, can sensitize them to TRAIL (196, 270). Cell infection by different viruses, such as reovirus, herpesvirus, HBV, and human immunodeficiency virus (HIV), has been shown to upregulate TRAIL and induce autocrine apoptosis (46, 173, 196, 235). Livers of patients with steatosis or HCV infection also display enhanced sensitivity to TRAIL-mediated apoptosis associated with increased expression of TRAIL receptors and upregulation of proapoptotic Bcl-2 proteins (270). Moreover, HCV core protein has been described to sensitize human hepatocellular carcinoma cells to TRAIL-mediated apoptosis via a mechanism dependent on sequential activation of caspase 8, Bid cleavage, and induction of mitochondria apoptosis signaling pathway (45).

In addition to promoting apoptosis of steatotic hepatocytes, TRAIL may also promote hepatocyte steatosis itself. For example, TRAIL expression in a murine model of HCV infection not only induces apoptosis of infected hepatocytes, but also leads to steatosis, a characteristic feature of liver diseases such as chronic hepatitis C, alcoholic liver disease, and nonalcoholic steatohepatitis (197). Moreover, TRAIL expression is also induced after alcohol consumption in mice and is associated with hepatic steatosis, but does not cause hepatocyte apoptosis, suggesting that TRAIL-mediated apoptosis and steatosis may be independently modulated after viral infection and alcohol intake (197). Several studies in vitro and in vivo have shown that TRAIL-induced apoptosis through DR5 also regulates cholestatic liver injury (106, 108, 109, 250) (Fig. 8). In particular, DR5 expression is increased in the liver of bile duct-ligated mice and in liver cells exposed to toxic bile acids (106, 108, 250). Cholestatic liver injury is also reduced in TRAIL-deficient mice following bile duct ligation (129). Importantly, TRAIL expression and apoptosis are significantly enhanced in cholangiocytes of human primary sclerosing cholangitis and primary biliary cirrhosis patients (250). These studies have also reported that treatment with an agonistic anti-DR5 monoclonal antibody triggers cholangiocyte apoptosis, and subsequently induced cholangitis and cholestatic liver injury (250). Notably, anti-DR5 monoclonal antibody-induced cholangitis exhibited the typical histological appearance of human primary sclerosing cholangitis. Thus TRAIL/DR5-mediated apoptosis may substantially contribute to chronic cholestatic disease, particularly primary sclerosing cholangitis.

6. TNF-α signaling

The ligand TNF-α is a pleiotropic cytokine mainly produced by macrophages, monocytes, and T cells in response to infection and inflammatory conditions and, occasionally, by other cell types, including hepatocytes. TNF-α exists in two biologically active forms, a membrane-bound form (mTNF-α) and a soluble form (sTNF-α), which bind to their cognate receptors TNF-R1 and TNF-R2 (p75/CD120b). However, since TNR-R2 lacks a functional death domain, only TNF-R1 is involved in transduction of the apoptotic signal (273).

In contrast to Fas and TRAIL receptors, signaling pathways from the TNF receptors are mainly pro-survival, although TNF-mediated apoptotic signals can be unmasked in certain pathological conditions. The complexity of the signaling triggered by TNF-α is demonstrated by
the diverse cellular responses to this cytokine, ranging from regulation of inflammation and immunity, to proliferation, differentiation, and apoptosis of many different target cells (272). For the purpose of this article, we will focus only on the apoptotic signaling. The reader is referred elsewhere for more comprehensive reviews on TNF signaling (96, 272).

Engagement of TNF-R1 rapidly leads to the assembly of an initial plasma membrane-bound complex (complex I) comprising the receptor, TNF-R1-associated protein with death domain (TRADD), RIP1, TNF-receptor associated factor 2 (TRAF2), cIAP-1, and, possibly, other molecules (190) (Fig. 9). This complex I induces activation of the inhibitor of \( \kappa \)B kinase (IKK) complex (including IKK\( \alpha \), IKK\( \beta \), and IKK\( \gamma \)/NEMO), which phosphorylates and promotes degradation of the NF-\( \kappa \)B regulatory subunit 1b\( \alpha \), resulting in activation of NF-\( \kappa \)B. NF-\( \kappa \)B, in turn, regulates the transcription of anti-apoptotic target genes, such as cFLIPL\( \alpha \), cIAP-1, XIAP, TRAF1, TRAF2, A20, A1, and Bcl-x\( _L \) that antagonize cell death (275). In addition to NF-\( \kappa \)B activation, complex I also signals activation of different mitogen-activated protein kinase (MAPK) cascades, such as p38 MAPK, extracellular regulated kinase (ERK), and c-Jun NH2-terminal kinase (JNK) (19) (Fig. 9). This complex I induces activation of the inhibitor of \( \kappa \)B kinase (IKK) complex (including IKK\( \alpha \), IKK\( \beta \), and IKK\( \gamma \)/NEMO), which phosphorylates and promotes degradation of the NF-\( \kappa \)B regulatory subunit 1b\( \alpha \), resulting in activation of NF-\( \kappa \)B. NF-\( \kappa \)B, in turn, regulates the transcription of anti-apoptotic target genes, such as cFLIPL\( \alpha \), cIAP-1, XIAP, TRAF1, TRAF2, A20, A1, and Bcl-x\( _L \) that antagonize cell death (275). In addition to NF-\( \kappa \)B activation, complex I also signals activation of different mitogen-activated protein kinase (MAPK) cascades, such as p38 MAPK, extracellular regulated kinase (ERK), and c-Jun NH2-terminal kinase (JNK) (19) (Fig. 9). Transient activation of JNK promotes proliferation, whereas prolonged JNK activation contributes to cell death (43), at least, in part, by promoting phosphorylation and proteasomal degradation of cFLIPL\( \alpha \) (37). NF-\( \kappa \)B activation normally regulates the strength and duration of TNF-\( \alpha \)-induced JNK activation and prevents sustained activation via transcription of target genes such as \( \text{xiap} \) and \( \text{gadd45} \) (56, 254) (Fig. 9). Indeed, IKK\( \beta \)-deficient mouse embryos display massive hepatocyte apoptosis at E14.5, whereas livers from IKK\( \beta \)/JNK1 double knockout mice show no apoptotic damage at the same embryonic stage (37). Moreover, JNK activation plays a role in the development of TNF-mediated hepatitis, as JNK-deficient mice, as well as mice treated with a specific JNK inhibitor, are resistant to different models of fulminant hepatitis depending on TNF-R1 activation (54, 175). Hepatocyte-specific impairment of NF-\( \kappa \)B activation also increases diethylnitrosamine-induced hepatocyte apoptosis, compensatory proliferation, and hepatocarcinogenesis via TNF-\( \alpha \)-mediated JNK1 activation (226).

The receptor-containing complex I is subsequently internalized, and TRADD, TRAP2, and RIP1 dissociate from the complex and associate with FADD and caspase 8 and 10 to form a cytosolic complex named complex II, which promotes caspase activation and apoptosis (190) (Fig. 9). Under normal circumstances, NF-\( \kappa \)B-induced cFLIPL\( \alpha \) associates with complex II, inhibiting the pro-apoptotic activity of caspase 8 (190). Therefore, TNF-induced apoptosis can only occur when the formation of complex I is prevented or disrupted, or when the cytoprotective activity of NF-\( \kappa \)B is inhibited. Indeed, a critical role for NF-\( \kappa \)B in preventing TNF-\( \alpha \)-mediated apoptosis was established in the liver during studies employing mice lacking the RelA/p65 component of NF-\( \kappa \)B, or IKK\( \beta \) (12, 160); embryonic lethality occurs in these mice due to massive hepatocyte apoptosis with liver degeneration. This phenotype was rescued by crossing these mice with TNF-R1 knockout mice (222). Thus NF-\( \kappa \)B activation is essential to prevent hepatocyte apoptosis by TNF-\( \alpha \).

TNF-\( \alpha \)-mediated NF-\( \kappa \)B activation can also be prevented by the pharmacological use of SMAC mimetics, small molecules designed to resemble the NH2 terminus of SMAC that inhibit XIAP, cIAP-1, and cIAP-2 (210, 268). These small molecules cause cIAP-1 and cIAP-2 autoubiquitination and proteasomal degradation (268); as a consequence, RIP1 is no longer ubiquitinated by cIAP-1 and cIAP-2 (17) and fails to phosphorylate NEMO and, thereby, to activate the IKK complex (Fig. 9). RIP1 is then released from complex I and associates with FADD and caspase 8, facilitating caspase 8 activation (210, 277). In liver cells, as previously described in Fas and TRAIL apoptosis, TNF-\( \alpha \)-mediated caspase 8 activation results in cleavage of Bid and MOMP with release of pro-apoptogenic factors in the cytosol (301, 302). In addition to Bid, recent studies suggested another BH3-only protein, Bim, may play a role in TNF-\( \alpha \)-mediated liver injury (132). TNF-\( \alpha \)-induced mitochondria dysfunction is also mediated by the lysosomal cathepsin B in hepatocytes (94). Indeed, both mitochondria permeabilization and apoptosis are abrogated in cathepsin B-deficient hepatocytes in vitro and in vivo after TNF-\( \alpha \) treatment (94, 98). Several experimental evidences suggest that other caspase-independent apoptosis-like pathways may also be activated by TNF-\( \alpha \) in the liver (126, 148).

7. **TNF-\( \alpha \) in liver pathobiology**

TNF-\( \alpha \)-induced hepatocyte apoptosis is implicated in a wide range of liver diseases including viral hepatitis, alcoholic hepatitis, ischemia/reperfusion liver injury, and fulminant hepatic failure (85). In chronic and acute liver injury, hepatocyte apoptosis results largely from overactivation of the immune system and generation of inflammatory cell products. TNF-\( \alpha \) is produced by the liver in response to hepatotoxins, such as carbon tetrachloride, galactosamine, and alcohol (51, 294). During chronic alcohol consumption, the number of liver NKT cells increases, promoting extensive hepatocyte apoptosis through both the Fas pathway and the TNF-R1 pathway (191). Expression of TNF-R1, however, is not enhanced in patients with alcoholic hepatitis, despite evidence of increased hepatocyte apoptosis (199). During ischemia/reperfusion (IR) injury, activated Kupffer cells release large amounts of TNF-\( \alpha \) and chemokines to recruit inflammatory cells. Although TNF-\( \alpha \) is involved in IR injury, as demonstrated by reduced IR liver damage in TNF-R1 knockout mice (224),
FIG. 9. TNF-R1 signaling pathways. Engagement of TNF-R1 by TNF-α induces recruitment of TRADD, RIP1, TRAF2, and c-IAP1/2 to the receptor to form the membrane-bound complex I. Two distinct pathways originate from the association of RIP1 and TRAF-2 to the receptor. The first one promotes survival by activation of the catalytic IKK complex, leading to phosphorylation of the NF-κB inhibitory protein IκBα and its degradation via the ubiquitin-proteasome pathway, allowing NF-κB to translocate to the nucleus and initiate transcription of anti-apoptotic target genes, such as cFLIP, cIAP-1, cIAP-2, TRAF1, TRAF2, XIAP, and Gadd45β. The second one leads to activation of JNK via the consequential activation of MEKK1/3 and MKK4/7. Activation of JNK is usually transient due to prompt inhibition by NF-κB-regulated proteins, such as XIAP and Gadd45β; however, sustained activation of JNK due to defects in NF-κB transcriptional activity results in c-FLIP degradation, enhanced caspase 8 activation, and apoptosis. Following the transient formation of complex I, the receptor is internalized by endocytosis and RIP1, TRAF2 and TRADD dissociated from TNF-R1, allowing the recruitment of FADD and caspase 8. The newly formed cytosolic complex (named complex II) promotes the activation of caspase 8, initiating the apoptotic cascade. This apoptotic pathway is inhibited by NF-κB-mediated expression of cFLIPL, which binds to caspase 8 and prevents its proteolytic activation.
the injury is likely not due to a direct toxic effect of TNF-α on the cells, but is rather the result of the recruitment and activation of inflammatory cells (47). Finally, TNF-α, together with other cytokines, is secreted by infiltrating cytotoxic T lymphocytes during HBV infection, which can promote apoptosis of viral-infected cells (187). Indeed, in a model of HBV transgenic hepatoma cell line, stimulation with TNF-α induces apoptosis (292). The pro-apoptotic effect of TNF-α in infected hepatocytes appears to be mediated by HBV protein X (HBVx) via activation of MAPK 1 (MKK1) and n-Myc (248).

B. Toll-like Receptors

1. Definition

Toll-like receptors, named for their similarity to the Toll gene product in *Drosophila*, are key pattern recognition receptor proteins in the innate immune system (18, 103, 212). They form a series of cell membrane and cytoplasmic receptors, which together provide a mechanism for recognition and response to fungal, bacterial, and viral products. Ten TLRs have been identified in humans and 13 in mice. TLRs and some of their ligands, including their primary ligand, are listed in Table 2. In addition to microbial recognition, TLRs also recognize endogenous DAMPs. Activation of the innate immune response is vital for host defense as well as priming of the adaptive immune system. However, excessive, continuous, or autoimmune activation of the innate immune system is a feature of many diseases. This sterile inflammatory response is also activated by DAMPs.

2. Toll-like receptors signaling

While understanding of TLR signaling is by no means complete, TLRs are known to be type I transmembrane proteins, single-spanning, with an extracellular NH2 terminus and an intracellular COOH terminus. TLRs form homodimers and, in some instances, heterodimers (TLR2 with TLR1 or TLR6) upon ligation. TLR signals emanate either from the cell surface (TLR1, TLR2, TLR4, TLR5, TLR6) or from the endolysosomal compartment (TLR3, TLR7, TLR9) (Fig. 7) (9). Upon ligation, they undergo a conformational change and recruit cytoplasmic adaptor proteins via a Toll/IL-1 receptor (TIR) domain. The proximal adaptor proteins that mediate TLR signaling are myeloid differentiation primary response gene 88 (MyD88), MyD88 adaptor-like protein (MAL, also known as TIR-domain-containing adapter protein; TIRAP), TIR domain-containing adaptor protein inducing interferon-β (TRIF), and TRIF-related adaptor molecule (TRAM). TIRAP and MyD88 mediate signals from most of the TLRs, except TLR3. TRIF mediates signals from TLR3, and with the adaptor TRAM, also from TLR4. Downstream of MyD88, via other adaptor proteins, regulatory kinases are activated, leading to activation of NF-κB and MAPK pathways. Downstream of TRIF, type I interferons are induced. TLR4 is the only TLR that can activate both pathways, the TIRAP-MyD88 pathway from the cell membrane, followed by the TRAM-TRIF pathway from the early endosome (128). TLR7, -8, and -9 engagement leads to IFN-α production downstream of MyD88.

3. Toll-like receptors in liver pathobiology

Most of the known TLRs are widely expressed on many cell types in the liver in addition to cells of the innate immune system, including hepatocytes, cholangiocytes, and stellate cells, and play a vital role in hepatic inflammation. TLR9 mediates hepatic stellate cell activation in response to apoptotic hepatocyte DNA (278). In acetaminophen-induced acute liver injury, activation of inflammatory pathways occurs in a TLR9-dependent manner (117) (Fig. 6). Furthermore, DAMPs are released from damaged hepatocytes in this model, presumably activating TLR9, although this has not been directly demonstrated (184). Liver inflammation upon intraportal injection of apoptotic hepatocyte DNA also occurs in a TLR9-dependent manner (117). These studies highlight the interconnectedness of hepatocyte cell death and the sterile inflammatory response in the liver. In an alcoholic hepatitis mouse model, Kupffer cell TLR4 activation mediates hepatic steatosis, inflammation, and injury (265). Chronic alcohol feeding upregulates many TLRs in the liver, and the use of TLR agonists augments liver injury (99). HCV infection is associated with reduced TLR7 expression in human liver samples, and viral proteins modulate TLR7 expression at a transcriptional level, thus favoring immune evasion (38). HCV-mediated TLR2 activation also favors immune subversion by dampening the TLR3 response (260). HBV replication is inhibited by activation of most TLRs, except TLR2 in a transgenic model.

---

**TABLE 2. Toll-like receptors and their ligands**

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Ligand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR1</td>
<td>Triacyl lipopeptides</td>
</tr>
<tr>
<td>TLR2</td>
<td>Triacyl lipopeptides, peptidoglycans, lipoteichoic acid</td>
</tr>
<tr>
<td>TLR3</td>
<td>Viral double-stranded RNA, poly IC</td>
</tr>
<tr>
<td>TLR4</td>
<td>Lipopolysaccharide, heparan, hyaluronate</td>
</tr>
<tr>
<td>TLR5</td>
<td>Bacterial flagellin</td>
</tr>
<tr>
<td>TLR6</td>
<td>Diacyl lipopeptides</td>
</tr>
<tr>
<td>TLR7</td>
<td>Single-stranded RNA, short double-stranded RNA</td>
</tr>
<tr>
<td>TLR8</td>
<td>Single-stranded RNA</td>
</tr>
<tr>
<td>TLR9</td>
<td>Unmethylated CpG oligodeoxynucleotides</td>
</tr>
<tr>
<td>TLR10</td>
<td>Unknown</td>
</tr>
<tr>
<td>TLR11</td>
<td>Proflin</td>
</tr>
<tr>
<td>TLR12</td>
<td>Unknown</td>
</tr>
<tr>
<td>TLR13</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
mouse model (119). In primary biliary cirrhosis, monocytes from patients demonstrate an exaggerated response to TLR ligands, suggesting a role for innate immunity in autoreactivity (182). Hepatic stellate cells are activated by the TLR4 agonist LPS, and mice lacking TLR4 demonstrate reduction in hepatic fibrosis following bile duct ligation (205, 236).

C. Lysosomal Pathway

1. Lysosomal pathway of apoptosis

For many years, mitochondria and nuclei have been thought to be the only key organelles in the initiation and execution of apoptosis. Although their role is still indisputable, many studies during the past decade have demonstrated also the importance of other organelles, such as the lysosomal/endosomal system (97) and the endoplasmic reticulum (see below), in the process. The lysosomal/endosomal compartment comprises single membrane-bound, cytosolic organelles responsible for degradation and recycling of cellular components. Over 50 different hydrolases are present in the lysosomal lumen, which work optimally at the lysosomal acidic pH, and carry out the digestion of all the major cellular macromolecules (7). The largest group of these hydrolases are the cathepsin proteases, which include the cysteine cathepsins (B, C, F, H, K, L, O, S, V, W, and X), the aspartic proteases cathepsin D and E, and the serine protease cathepsin G (262). In the early stages of apoptosis following exposure to different stimuli, lysosomal proteases from the cathepsin family frequently translocate from the lysosomal lumen to the cytosol and nucleus. This release is associated with LMP and, contrary to what occurs during necrosis, is a moderate phenomenon that likely affects only a subpopulation of susceptible lysosomes rather than all lysosomes (283). The mechanisms underlying LMP are still largely unknown, but several evidences suggest that the release of lysosomal enzymes occurs via non-specific mechanisms, such as increased membrane permeabilization or pore formation, rather than via specific transporters across the membrane. Genetic and pharmacological inhibition of two of the most highly expressed cathepsins, cathepsin B and D, has been proven effective in blocking apoptosis in several different models, including p53-dependent and -independent cell death as well as oxidative stress-, IFN-γ-, TNF-α-, Fas-L, and TRAIL-induced cell death, suggesting that these enzymes actively participate in the pathway and their release is not just the result of a late degenerative process (20, 61, 78, 94, 125, 219, 238, 284). In some models, apoptosis appears to be entirely cathepsin dependent (27, 34, 78), whereas in others both caspases and cathepsins are required for apoptosis initiation and execution (70, 94). Lysosomal permeabilization is often followed by mitochondrial dysfunction and release of pro-apoptogenic factors (20, 26, 27, 94, 300). Therefore, in many cases, cathepsins seem to function upstream of the mitochondria by provoking MOMP, possibly via direct activation of Bid or Bax (20, 104, 246). This sequence of subcellular alterations (lysosomal permeabilization → mitochondrial permeabilization → caspase activation → cell death) is known as the lysosomal pathway of apoptosis (Fig. 10).

2. Lysosomal pathway of apoptosis in liver pathobiology

The contribution of the lysosomal pathway of apoptosis appears to be particularly significant in liver
cell death in pathological conditions. LMP with release of lysosomal content has been shown in several liver diseases in association with increased apoptosis. In particular, cathepsin B seems to play a central role in the induction and progression of liver damage of different etiologies, as inhibition of cathepsin B significantly reduces hepatocyte apoptosis and liver injury in animal models of cholestasis (32), TNF-α-mediated acute liver failure (98), NASH (74, 75), and cold ischemia/warm reperfusion injury in steatotic livers (10). Cathepsin B is one of the most abundant lysosomal cysteine cathepsins and retains most of its enzymatic activity and stability even at cytosolic pH, which might explain its prominent role in the apoptotic process (261). In many of these models, apoptosis is triggered after the engagement of a death receptor, suggesting lysosomes are an important component of the death receptor-dependent apoptotic cascade in the liver (Fig. 10). In particular, Fas and DR5 are activated by bile acids, the bile component mainly responsible for tissue damage in cholestatic livers (70, 107, 108), whereas Fas, DR5, and the TNF/TNF-R system mediate cytotoxicity in fatty livers (74, 177). How engagement of death receptors signals LMP is still under investigation; however, recent studies have shown that internalization of the TRAIL/DR5 complex is required for lysosomal permeabilization in liver cancer cells (3). The subsequent trafficking of the complex to the lysosomes would bring the apoptotic machine in close proximity to the lysosomal membrane, allowing membrane permeabilization to occur, perhaps via formation of pores with mechanisms similar to those proposed for the outer mitochondrial membrane. Indeed, TRAIL-induced LMP in cholangiocarcinoma cells requires JNK-mediated activation of Bim and Bax (284). Likewise, TNF-α-mediated LMP is strongly reduced in Bid-deficient mouse hepatocytes (93, 282). Finally, hepatocyte treatment with toxic free fatty acids (an in vitro model of liver steatosis) results in Bax translocation to the lysosomes, reduced expression of the Bax antagonist Bcl-XL, and LMP, which can be prevented by pharmacological or genetic inhibition of Bax (75).

D. Endoplasmic Reticulum Stress

1. Endoplasmic reticulum stress signaling

Endoplasmic reticulum (ER) stress, defined in the context of the accumulation of misfolded proteins in the lumen of the ER, activates a series of ER-to-nucleus signals, collectively termed the unfolded protein response (UPR) (221, 231) (Fig. 11). Perturbations in ER homeostasis, such as calcium depletion, inhibition of glycosylation, alterations in the redox state, and lipid loading of the ER, also activate the UPR. Accumulation of misfolded ER proteins is sensed by three resident transmembrane proteins, inositol requiring protein 1α (IRE1α), ds-RNA-activated protein kinase (PKR) like ER kinase (PERK), and activating transcription factor 6 alpha (ATF6α) (Fig. 11). Release from inhibitory binding with the chaperone BiP activates all three sensors. PERK phosphorylates the eukaryotic initiation factor 2α (eIF2α), leading to a global reduction in translation due to inhibition of the initiation of translation. Activating transcription factor 4 (ATF4) is preferentially translated following eIF2α phosphorylation, activating ER chaperone genes, ER associated protein degradation (ERAD) pathway genes, amino acid metabolism genes, as well as the transcription factor C/EBP homologous protein (CHOP). IRE1α has kinase as well as endoribonuclease activity; it is activated by transautophosphorylation, leading to the unconventional splicing of the transcription factor X-box binding protein-1 (XBP1) mRNA and formation of transcriptionally active spliced XBP1 (XBP1s). Spliced XBP1 activates chaperone UPR target genes, including chaperones and ERAD pathway genes. ATF6α is cleaved in the Golgi to form a transcriptionally active fragment that traffics to the nucleus to activate UPR target genes. All three arms of the UPR are aimed at adaptation and restoration of ER homeostasis; however, sustained ER stress can lead to apoptosis.

The molecular mechanisms of ER stress-induced apoptosis are not fully understood; however, potentially apoptotic pathways are activated as part of the UPR. Deletion of the transcription factor CHOP offers protection from ER stress-induced apoptosis (303). Growth arrest and DNA damage-inducible protein (Gadd34) transcription occurs downstream of CHOP. Gadd34 binds protein phosphatase-1 and enhances eIF2α dephosphorylation, leading to restoration of translation. Thus the entry of nascent proteins into stressed ER could be further disruptive (183). CHOP can also enhance expression of the TRAIL receptor DR5 and the proapoptotic Bcl-2 family protein Bim (215, 289). Overexpression of CHOP in cell lines sensitizes to ER stress-induced apoptosis with reduced cellular glutathione and decreased expression of the antiapoptotic protein Bcl-2 (188). IRE1α can recruit the adaptor protein TRAF2 activating JNK and NF-κB, both of which can mediate apoptosis (116, 267). Alterations in ER calcium homeostasis and activation of caspase 12 are other mechanisms for ER stress-induced apoptosis (198, 201, 216).

2. ER stress in liver pathobiology

ER stress is a feature of liver disease. An example of ER stress-associated liver injury is that mediated by FFA in the metabolic syndrome (Fig. 12). Saturated FFA in-
duce an ER stress response (276, 280, 281), which acti-
vates PERK and IRE1α. PERK activation results in CHOP
expression that not only induces expression of DR5 and
Fas (177), but also of BH3-only protein Bim (178). In
addition, IRE1α promotes sustained JNK activation re-
sulting in PUMA expression (35). All of these cascades
likely contribute to the lipoapoptosis observed in human
NASH.

In obese patients, UPR markers are detected in the
liver and correlate with weight loss (92). Hepatitis C viral
replicons can also activate the UPR, and HCV core protein
can induce ER calcium depletion and apoptosis (14, 255).
Intrahepatic cholestasis in mice is associated with activa-
tion of the UPR (22). In the bile duct-ligation model of
cholestatic liver injury, CHOP-deficient mice demonstrate
attenuation of hepatocyte cell death, liver injury, and
fibrosis (253). In alcohol-induced liver injury in mice, the
absence of CHOP abrogates hepatocyte apoptosis, with-
out affecting hepatocyte steatosis (123). Furthermore,
mice with genetic absence of any of the UPR sensors
develop microvesicular hepatic steatosis upon acute ER
stress (225).

V. THERAPEUTIC STRATEGIES FOR
LIVER INJURY

The optimal therapeutic strategy for liver diseases is to
directly inhibit the inciting mechanism for the liver
injury. This is quite feasible for viral hepatitis where
direct and indirect antiviral therapies are employed to
treat human disease. However, the pathophysiological
mechanisms for many cholestatic liver diseases (e.g.,
primary sclerosing cholangitis, primary biliary cirrho-
sis), metabolic diseases such as NASH, acute alcohol-
mediated hepatitis, etc. remain to be identified. In ad-
dition, many patients with viral hepatitis fail antiviral
therapy. Thus there is a role for the development of
hepatoprotective agents. Such agents, by inhibiting
mechanisms of liver injury, would retard fibrotic pro-

FIG. 11. Unfolded protein response and cell death. Endoplasmic reticulum (ER) stress, such as the accumulation of misfolded proteins
in the ER lumen, activates the unfolded protein response (UPR), aimed at restoring ER homeostasis through translational and transcriptional
pathways. The UPR sensors IRE1α, PERK, and ATF6α activate these pathways. Activation of IRE1α leads to the unconventional splicing of
the transcription factor XBP1 to the transcriptionally active spliced XBP1 (XBP1s), which activates UPR target genes aimed at restoration of
ER homeostasis. Via the adaptor protein TRAF2, IRE1α can activate JNK. ATF6α is cleaved in the Golgi to an active transcription factor which
induces expression of UPR target genes, also aimed at restoration of homeostasis. Phosphorylation of eIF2α by PERK results in attenuation
of translation and selective translation of ATF4 and its target CHOP. Failure of restoration of ER homeostasis results in cell death. Some
possible mechanisms include CHOP-induced expression of the proapoptotic protein Bim, and DR5, perturbations in ER calcium, and
JNK-induced cell death. The anti-apoptotic protein Bax inhibitor 1 (BI-1) is a negative regulator of IRE1α, as well as negative regulator of
ER-stress induced cell death.
Tegression of the liver disease potentially preventing cirrhosis, portal hypertension, and even hepatocellular cancer. To date, the only example of a hepatoprotective agent used to treat a liver disease is the widespread use of ursodeoxycholate as primary therapy for primary biliary cirrhosis (154); indeed, ursodeoxycholate may be considered the first anti-apoptotic agent employed to treat liver diseases (220). We will limit this discussion to strategies that have proven viable in the pharmaceutical industry, namely, the potential use of small molecule protease and kinase inhibitors (Table 3). Potentially, antibodies could be used to target death ligands and receptors, but they target very specific molecules and likely would not be useful in complex pathophysiological conditions where often multiple pathways are operating simultaneously.

A. Protease Inhibitors

1. Caspase inhibitors

As apoptosis plays a key role in many liver diseases and is largely caspase mediated, pharmacological caspase inhibitors are attractive hepatoprotective drugs for the treatment of human liver diseases. Indeed, pan-caspase inhibitors attenuate hepatic injury and fibrosis in preclinical models of cholestasis and non-alcoholic liver disease (30, 288). In a short-term trial, a pan-caspase inhibitor reduces serum transaminases in patients with HCV without affecting viral replication (186, 211). A pan-caspase inhibitor was shown to reduce liver preservation injury during rodent and human organ transplantation (11, 114). Thus these agents clearly warrant further consideration for the treatment of human liver diseases.

Although there is a theoretical concern that apoptosis inhibition by caspase inhibitors would promote carcinogenesis, this is unlikely. As mentioned above, there are two canonical pathways of apoptosis, a death receptor-mediated pathway and a mitochondrial pathway. The death receptor pathway is dependent on caspase 8 (132), while the mitochondrial pathway is mediated by caspase 9. In the liver, the genetic absence of caspase 8 attenuates hepatitis in experimental models mediated by death ligands (132, 297). In contrast, caspase 9 deletion delays, but does not prevent, cell death (65). Thus a caspase inhibitor would only be expected to inhibit death receptor-mediated apoptosis. As knockout murine models of various death receptors do not develop spontaneous cancers, caspase inhibitors should be safe with regard to cancer risk.

2. Cathepsin B inhibitors

Cathepsin B is a lysosomal protease that has been implicated in lysosomal disruption and apoptosis (94, 95, 282, 284). Preclinical studies showed that genetic and pharmacological inhibition of cathepsin B reduce TNF-α-mediated acute liver injury and improve survival in a mouse model (98). Likewise, cathepsin B inactivation attenuates liver injury, inflammation, and fibrogenesis after bile duct ligation, a model of cholestatic liver injury (32). Because the cathepsin B knockout animal does not have a spontaneous phenotype, a cathepsin B inhibitor should not have target toxicity in humans. Cathepsin B inhibitors, for the treatment of cholestatic...
liver diseases and, potentially, even for NASH, are an attractive strategy (74).

3. **Matrix metalloprotease inhibitors**

Matrix metalloprotease (MMP) inhibition is a potential strategy to minimize liver injury and reduce hepatic fibrogenesis. TNF-α converting enzyme (TACE) is a MMP required for the release of cell-bound TNF-α into the circulation. TNF-α also promotes the induction and activation of other MMP which further enhances liver injury. Indeed, inhibition of MMP activity blocks lethal hepatitis and apoptosis in murine models of TNF-α-associated acute liver injury (286). Also, a broad-spectrum MMP inhibitor reduces hepatocyte apoptosis and fibrosis in the bile duct-ligated mouse (130). A MMP inhibitor is currently in early phase trials for the treatment of HCV-associated liver disease.

**B. Kinase Inhibitors**

1. **JNK inhibitors**

Sustained JNK activation has been implicated in multiple forms of hepatocyte cell death, including drug-induced liver injury, FFA-mediated liver cytotoxicity, ER stress-associated disease states, I/R injury, and TNF-α-induced liver damage (50, 101, 178, 179, 230, 233, 234, 264). In addition, JNK inhibition is also antifibrotic in the liver (138). Although JNK inhibitors are widely employed in cell system studies, their use in vivo is limited. Also, multiple isoforms of JNK are encoded by two genes, JNK1 and -2, in the liver, and inhibition of one, the other, or both, may be necessary for different forms of injury. For example, in a model of NASH, JNK1 promotes liver injury while JNK2 is protective (230). Thus JNK isoform-specific inhibitors may be necessary to treat human liver diseases.

2. **Necrostatins**

RIP1 and -3 kinases have been implicated in cell death, especially that by death receptors (57). Recently, a group of small molecules termed necrostatins were found to inhibit cell death by allosterically inhibiting RIP kinases (60). Necrostatin-1 is a highly selective inhibitor of RIP1. Given the emerging role of RIP1 in various forms of necrotic cell injury, these observations suggest small molecular compounds can be developed to inhibit RIP kinases and prevent hepatic necrosis.

**VI. CONCLUSIONS**

This review focuses on current concepts of hepatocyte cytotoxicity, a common occurrence in clinical practice. There is much yet to be learned about liver injury, especially the complex interplay between the immune system and the hepatocyte in these pathophysiological states. Also, the mechanisms by which cell death promotes hepatic fibrosis are likely more multifaceted and nuanced than current concepts suggest. Rational therapeutic hepatoprotective strategies must be predicated on a thorough understanding of how liver injury occurs. As this information becomes available, clinical trials with appropriate end points can be developed to hopefully establish therapeutic approaches to minimize hepatic injury and its sequelae. Hopefully, this review will serve as a guide in this quest.

**ACKNOWLEDGMENTS**

Address for reprint requests and other correspondence: G. J. Gores, College of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905 (e-mail: gores.gregory@mayo.edu).

**GRANTS**

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) RO1 Grants TABLE 3. **Anti-apoptotic therapeutic strategies for liver diseases**

<table>
<thead>
<tr>
<th>Drug Type</th>
<th>Liver Diseases</th>
<th>Clinical Trial</th>
<th>Reference Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ursodeoxycholate</td>
<td>PBC</td>
<td>Phase III</td>
<td>146, 162</td>
</tr>
<tr>
<td></td>
<td>PSC</td>
<td>Phase III</td>
<td>49, 165</td>
</tr>
<tr>
<td></td>
<td>NASH</td>
<td>Phase II</td>
<td>8, 164</td>
</tr>
<tr>
<td></td>
<td>Cholestasis of pregnancy</td>
<td>Phase II</td>
<td>86, 87</td>
</tr>
<tr>
<td></td>
<td>Chronic HCV</td>
<td>Phase I/II</td>
<td>13, 203</td>
</tr>
<tr>
<td>Caspase inhibitors</td>
<td>Chronic HCV</td>
<td>Phase II</td>
<td>211</td>
</tr>
<tr>
<td></td>
<td>I/R injury</td>
<td>Phase II</td>
<td>11</td>
</tr>
<tr>
<td>Cathepsin B inhibitors</td>
<td>I/R injury</td>
<td>Preclinical</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Fibrosis</td>
<td>Preclinical</td>
<td>32</td>
</tr>
<tr>
<td>MMP inhibitors</td>
<td>HCV</td>
<td>Phase II</td>
<td>138</td>
</tr>
<tr>
<td>JNK inhibitors</td>
<td>Fibrosis</td>
<td>Preclinical</td>
<td>138</td>
</tr>
<tr>
<td>Necrostatins</td>
<td>Necrotic damage (?)</td>
<td>No studies in liver</td>
<td></td>
</tr>
</tbody>
</table>
REFERENCES


4. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Platelet-derived growth factor (PDGF) and PDGF receptor b (PDGFRb) are co-expressed by human liver stellate cells and are required for stellate cell activation in vitro. J Hepatol 41: 75–81, 2004.


1189

HEPATOCELL CYTOTOXITY

HEPATOCELL CYTOTOXICITY 1191


Tchopp J, Irmler M, Thome M. Inhibition of Fas death signals by FLIPs. Curr Opin Immunol 10: 552–558, 1998.


Tschopp J, Irmler M, Thome M. Inhibition of Fas death signals by FLIPs. Curr Opin Immunol 10: 552–558, 1998.


Weberbargen NW, Guicciardi ME, Bronk SF, Gores GJ. Tumor necrosis factor-alpha-associated lysosomal permeabilization is caused by 10.220.33.3 on April 9, 2017 http://physrev.physiology.org/ Downloaded from


